Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RIMMYRAH 10 MG/ML SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RIMMYRAH 10 MG/ML SOLUCION INYECTABLE

Approved

STANDARD

RIMMYRAH 10 MG/ML SOLUCION INYECTABLE

Qilu Pharma Spain S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 27, 2024
Approval ID: 77c0d82b9b5bb7ec
Company: Qilu Pharma Spain S.L.
Type: Standard

Approval Details

Approval Id: 77c0d82b9b5bb7ec
Drug Cima Aemps Name: RIMMYRAH 10 MG/ML SOLUCION INYECTABLE
Register Number: 1231779002
Holder Company Name: Qilu Pharma Spain S.L.
Marketing Company Name: Orion Pharma S.L.
Holder Company Detail Path: /organization/qilu-pharma-spain-sl
Authorization Date: 2024-03-27
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 10 mg/ml
Route Of Administration: VÍA INTRAVÍTREA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Qilu Pharma Spain S.L.
Company Detail Path: /organization/qilu-pharma-spain-sl

Company Information

Pharmaceutical Company Name: QILU PHARMA SPAIN SL.
Country Name: Spain
City Name: madrid,madrid,country_es
Address: PASEO CASTELLANA, 40 - PISO 8

Active Ingredients

RANIBIZUMAB

2,3 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 27, 2024

Approval ID

77c0d82b9b5bb7ec

Type

Standard

Back to CIMA-AEMPS Approvals